| Literature DB >> 30739973 |
Daniel Rogers Mukiibi1,2, Titus Alicai2, Robert Kawuki2, Geoffrey Okao-Okuja2, Fred Tairo3, Peter Sseruwagi3, Joseph Ndunguru3, Elijah Miinda Ateka1.
Abstract
Cassava brown streak disease (CBSD) and cassava mosaic disease (CMD) are two viral diseases that cause severe yield losses in cassava of up to 100%, thereby persistently threatening food and income security in sub-Saharan Africa. For effective management of these diseases, there is a critical need to develop and deploy varieties with dual resistance to CBSD and CMD. In this study, we determined the response of advanced breeding lines to field infection by cassava brown streak viruses (CBSVs) and cassava mosaic begomoviruses (CMBs). This aim helped in identifying superior clones for downstream breeding. In total, 220 cassava clones, three in uniform yield trials (UYTs) and 217 in a crossing block trial (CBT), were evaluated for virus and disease resistance. Field data were collected on disease incidence and severity. To detect and quantify CBSVs, 448 and 128 leaf samples from CBSD symptomatic and symptomless plants were analyzed by reverse transcription PCR and real-time quantitative PCR, respectively. In addition, 93 leaf samples from CMD symptomatic plants in the CBT were analyzed by conventional PCR using CMB species-specific primers. In the CBT, 124 (57%) cassava clones did not express CMD symptoms. Of the affected plants, 44 (55%) had single African cassava mosaic virus infection. Single Cassava brown streak virus (CBSV) infections were more prevalent (81.6%) in CBT clones than single Ugandan cassava brown streak virus (UCBSV) infection (3.2%). Of the three advanced clones in the UYT, NAROCASS 1 and NAROCASS 2 had significantly lower (P < 0.05) CBSD severity, incidence, and CBSV load than MH04/0300. In the UYT, only 22% of samples tested had CBSVs, and all showed a negative result for CMBs. The low disease incidence, severity, and viral load associated with NAROCASS 1 and NAROCASS 2 is evidence of their tolerance to both CBSD and CMD. Therefore, these two cassava clones should be utilized in CBSD and CMD management in Uganda, including their utilization as progenitors in further virus resistance breeding.Entities:
Keywords: Cassava brown streak disease; Cassava mosaic disease; Incidence; Severity; Tolerance; Virus load
Year: 2019 PMID: 30739973 PMCID: PMC6358137 DOI: 10.1016/j.cropro.2018.09.015
Source DB: PubMed Journal: Crop Prot ISSN: 0261-2194 Impact factor: 2.571
Mean incidence (%) of cassava brown streak disease on cassava clones for uniform yield trials, 11 months after planting.
| Clone | Location | Mean | l.s.d. | F. pr. | |||
|---|---|---|---|---|---|---|---|
| Arua | Kaberamaido | Kamuli | Wakiso | ||||
| MH04/0300 | 33.7 | 63.9 | 0 | 34.8 | 33.1 | 28.76 | 0.004 |
| NAROCASS 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| NAROCASS 2 | 0 | 4.2 | 0 | 0 | 1 | 3.748 | 0.078 |
| NASE 14 | 4.1 | 2.4 | 0 | 11.1 | 4.4 | 12.64 | 0.308 |
| Mean | 9.4 | 17.6 | 0 | 11.5 | 9.6 | 7.3 | <0.001 |
| l.s.d. | 19.69 | 16.44 | 0 | 18.52 | 7.3 | 14.6 | |
| F. pr. | 0.007 | <0.001 | 0.004 | <0.001 | <0.001 | ||
l.s.d. is the least significant difference at P = 0.05.
F. pr. is the probability of obtaining the observed variance ratio (P value).
Fig. 1Variability and distribution of CBSD severity and incidence with time among cassava clones of the uniform yield trial.
Fig. 2Progress in CBSD incidence (%) and severity of cassava in uniform yield trial locations at 5, 8, and 11 months after planting.
Mean severity of cassava brown streak disease on cassava clones for uniform yield trials, 11 months after planting.
| Clone | Location | Mean | l.s.d. | c.v. (%) | F. pr. | |||
|---|---|---|---|---|---|---|---|---|
| Arua | Kaberamaido | Kamuli | Wakiso | |||||
| MH04/0300 | 3.0 | 3.5 | 1.0 | 3.3 | 2.688 | 0.6208 | 14.8 | <0.001 |
| NAROCASS 1 | 1.0 | 1.0 | 1.0 | 1.0 | 1 | 0 | 0 | 0 |
| NAROCASS 2 | 1.0 | 2.5 | 1.0 | 1.0 | 1.375 | 0.3523 | 16.3 | <0.001 |
| NASE 14 | 2.3 | 2.5 | 1.0 | 2.0 | 1.96 | 0.683 | 20.8 | 0.005 |
| Mean | 1.833 | 2.37 | 1.0 | 1.812 | 1.755 | 0.2088 | <0.001 | |
| l.s.d. | 0.4068 | 0.894 | 0 | 0.4315 | 0.2088 | 0.4177 | ||
| c.v. (%) | 14.1 | 22.5 | 0 | 15.1 | 16.7 | |||
| F. pr. | 0.014 | 0.002 | 0 | <0.001 | <0.001 | <0.001 | ||
l.s.d. is the least significant difference at P = 0.05.
c.v. is the coefficient of variation.
F. pr. is the probability of obtaining the observed variance ratio (P value).
Prevalence of CBSVs in samples collected from cassava clones at uniform yield trial locations.
| Symptomatic | Nonsymptomatic | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Location | Clone | CBSV | UCBSV | CBSV + UCBSV | CBSV | UCBSV | CBSV + UCBSV | Total positive (%) | ||
| Arua | MH04/0300 | 19 | 10 | 0 | 6 | 9 | 3 | 0 | 5 | 24 (96) |
| NAROCASS 1 | 0 | 0 | 0 | 0 | 28 | 0 | 0 | 0 | 0 (0) | |
| NAROCASS 2 | 2 | 1 | 0 | 0 | 26 | 1 | 0 | 0 | 2 (8) | |
| NASE 14 | 4 | 3 | 0 | 1 | 24 | 0 | 0 | 0 | 4 (16) | |
| Kaberamaido | MH04/0300 | 21 | 16 | 0 | 0 | 7 | 7 | 0 | 0 | 23 (92) |
| NAROCASS 1 | 0 | 0 | 0 | 0 | 28 | 0 | 0 | 0 | 0 (0) | |
| NAROCASS 2 | 4 | 2 | 0 | 0 | 24 | 2 | 0 | 0 | 4 (16) | |
| NASE 14 | 12 | 8 | 0 | 0 | 16 | 2 | 0 | 0 | 10 (40) | |
| Kamuli | MH04/0300 | 0 | 0 | 0 | 0 | 28 | 0 | 0 | 0 | 0 (0) |
| NAROCASS 2 | 0 | 0 | 0 | 0 | 28 | 0 | 0 | 0 | 0 (0) | |
| NAROCASS 1 | 0 | 0 | 0 | 0 | 28 | 0 | 0 | 0 | 0 (0) | |
| NASE 14 | 0 | 0 | 0 | 0 | 28 | 0 | 0 | 0 | 0 (0) | |
| Wakiso | MH04/0300 | 17 | 14 | 0 | 0 | 11 | 5 | 0 | 2 | 21 (84) |
| NAROCASS 1 | 0 | 0 | 0 | 0 | 28 | 0 | 0 | 0 | 0 (0) | |
| NAROCASS 2 | 0 | 0 | 0 | 0 | 28 | 0 | 0 | 0 | 0 (0) | |
| NASE 14 | 9 | 7 | 0 | 0 | 19 | 3 | 0 | 0 | 10 (40) | |
| Total | 88 | 61 | 0 | 7 | 360 | 23 | 0 | 7 | 98 (20.08) | |
– Number of samples.
CBSV titers (fold changes) in cassava genotypes for uniform yield trials at 5 and 11 months after planting (MAP).
| Clone | Location | |||||||
|---|---|---|---|---|---|---|---|---|
| Arua | Kaberamaido | Kamuli | Wakiso | |||||
| 5 MAP | 11 MAP | 5 MAP | 11 MAP | 5 MAP | 11 MAP | 5 MAP | 11 MAP | |
| MH04/0300 | 0.377 | 12.19 | 6.706 | 20.56 | 0.109 | 0.91 | 0.579 | 9.04 |
| NAROCASS 1 | 0.04 | 0.02 | 0.064 | 0.02 | 0.008 | 0.01 | 0.018 | 0.01 |
| NAROCASS 2 | 0.032 | 0.06 | 0.089 | 1.4 | 0.011 | 0.01 | 0.024 | 0.76 |
| NASE 14 | 0.132 | 5.53 | 0.578 | 7.32 | 0.03 | 0.04 | 0.114 | 1.56 |
| Mean | 0.145 | 4.45 | 1.859 | 7.32 | 0.04 | 0.24 | 0.184 | 2.84 |
| l.s.d. | 0.3218 | 2.971 | 0.89 | 3.706 | 0.0997 | 1.713 | 0.849 | 4.321 |
| F pr | 0.113 | <0.001 | <0.001 | <0.001 | 0.133 | 0.467 | 0.337 | 0.013 |
l.s.d. is the least significant difference at P = 0.05.
F. pr. is the probability of obtaining the observed variance ratio (P value).
UCBSV titers (fold changes) in cassava genotypes for uniform yield trials at 5 and 11 months after planting (MAP).
| Clone | Location | |||||||
|---|---|---|---|---|---|---|---|---|
| Arua | Kaberamaido | Kamuli | Wakiso | |||||
| 5 MAP | 11 MAP | 5 MAP | 11 MAP | 5 MAP | 11 MAP | 5 MAP | 11 MAP | |
| MH04/0300 | 3.56 | 2.15 | 14.1 | 20.1 | 0.16 | 0.43 | 0.03 | 0.055 |
| NAROCASS 1 | 0.67 | 0.06 | 0.1 | 0.2 | 0.03 | 0.022 | 0.04 | 0.006 |
| NAROCASS 2 | 0.03 | 0.01 | 0.1 | 0 | 0.36 | 0.003 | 0.87 | 0.156 |
| NASE 14 | 0.28 | 12.96 | 0 | 4.6 | 0.14 | 0.238 | 0.06 | 0.057 |
| Mean | 1.13 | 3.79 | 3.6 | 6.2 | 0.17 | 0.173 | 0.25 | 0.068 |
| l.s.d. | 5.726 | 2.554 | 27.69 | 12.27 | 0.788 | 0.4913 | 1.551 | 0.2604 |
| F pr | 0.399 | <0.001 | 0.481 | 0.029 | 0.712 | 0.19 | 0.446 | 0.518 |
l.s.d. is the least significant difference at P = 0.05.
F. pr. is the probability of obtaining the observed variance ratio (P value).
Fig. 3Amplification plots for (a) CBSV, UCBSV, and COX; (b) COX, the housekeeping gene; (c) CBSV; and (d) UCBSV.
Cassava brown streak disease root incidence, mean severity, maximum severity, harvest index, and yield performance of clones at uniform yield trial locations.
| Clone | CBSDRi | Mean_CBSDRs | max_CBSDRs | Harvest_Index | Yield_T_ha | |
|---|---|---|---|---|---|---|
| Kaberamaido | MH04/0300 | 28.3 | 1.8 | 4.0 | 0.5 | 7.4 |
| NAROCASS 1 | 2.3 | 1.0 | 2.0 | 0.7 | 22.8 | |
| NAROCASS 2 | 3.7 | 1.1 | 3.0 | 0.6 | 13.9 | |
| NASE 14 | 12.5 | 1.4 | 4.5 | 0.5 | 22.2 | |
| mean | 11.7 | 1.3 | 3.4 | 0.6 | 16.6 | |
| l.s.d. | 26.9 | 0.8 | 2.0 | 0.2 | 6.6 | |
| cv% | 128.2 | 35 | 41 | 20.3 | 28.2 | |
| F pr. | 0.106 | 0.11 | 0.103 | 0.282 | 0.001 | |
| Kamuli | MH04/0300 | 0.6 | 1.0 | 1.3 | 0.5 | 14.8 |
| NAROCASS 1 | 1.9 | 1.0 | 2.5 | 0.5 | 28.9 | |
| NAROCASS 2 | 1.9 | 1.0 | 1.8 | 0.5 | 16.7 | |
| NASE 14 | 3.8 | 1.1 | 2.8 | 0.5 | 30.8 | |
| mean | 2.1 | 1.0 | 2.1 | 0.5 | 22.8 | |
| l.s.d. | 2.3 | 0.1 | 1.6 | 0.1 | 11.9 | |
| cv% | 70.2 | 3.2 | 50 | 13.2 | 32.6 | |
| F pr. | 0.073 | 0.267 | 0.22 | 0.214 | 0.027 | |
| Arua | MH04/0300 | 9.8 | 1.1 | 4.0 | 0.6 | 31.0 |
| NAROCASS 1 | 0.2 | 1.0 | 1.3 | 0.6 | 53.3 | |
| NAROCASS 2 | 4.6 | 1.1 | 2.5 | 0.6 | 20.9 | |
| NASE 14 | 7.5 | 1.2 | 5.0 | 0.6 | 34.2 | |
| mean | 5.2 | 1.1 | 3.1 | 0.6 | 34.9 | |
| l.s.d. | 7.1 | 0.1 | 1.2 | 0.1 | 22.9 | |
| cv% | 84.2 | 6.2 | 23.1 | 6 | 42.7 | |
| F pr. | 0.065 | 0.018 | <0.001 | 0.039 | 0.057 | |
| Wakiso | MH04/0300 | 68.0 | 3.8 | 5.0 | 0.6 | 39.4 |
| NAROCASS 1 | 3.9 | 2.0 | 4.0 | 0.5 | 55.6 | |
| NAROCASS 2 | 4.5 | 2.1 | 3.0 | 0.4 | 23.3 | |
| NASE 14 | 41.9 | 3.1 | 5.0 | 0.4 | 42.3 | |
| mean | 29.6 | 2.8 | 4.3 | 0.5 | 40.2 | |
| l.s.d. | 60.4 | 1.7 | 2.8 | 0.2 | 20.3 | |
| cv% | 73.5 | 22.7 | 23.5 | 13.1 | 18.2 | |
| F pr. | 0.103 | 0.113 | 0.281 | 0.115 | 0.05 |
CBSDRi = cassava brown streak disease root incidence, Mean_CBSDRs = mean cassava brown streak disease root severity, max_CBSDRs = maximum cassava brown streak disease root severity, Yield_T_ha = yield in tonnes per hectare, l.s.d. = least significant difference at P = 0.05, c.v. = coefficient of variation, F. pr. = probability of obtaining the observed variance ratio (P value).
Fig. 4CMD severity (a) and incidence (b) at 12 months after planting on 217 genotypes assessed in the crossing block trial.
Fig. 5CBSD severity (a) and incidence (b) at 12 months after planting on 217 genotypes assessed in the crossing block trial.
Fig. 6Detection of (a) CBSVs and (b) CMBs in the cassava clones evaluated in the crossing block trial.